Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

Study acronym: EV03/ANRSVAC20
StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseasesv9
  2. Trial status: Active, Not Recruiting to Completedv8 Show 4 more changesShow less
    • Enrollment target: estimated 140 to confirmed 147
    • Eligibility criteria expanded, about 22 words
    • Study description revised
    • Study arms: 0 to 2
  3. Study sites: 3 to 2
    • Start date: Nov 2007 to Jul 2007
    • Secondary endpoints: details revised at 2 of 7 entries
    v7
  4. Start date: Jun 2007 to Nov 2007v6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Mar 2009 to Dec 2008
    • Study completion date: Mar 2009 to Oct 2009
    • Site details revised at 3 of 3 sites
  5. Primary completion date: Mar 2009
    • Site details revised at 1 of 3 sites
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study completion date: Feb 2009 to Mar 2009
    • Start date: Jul 2007 to Jun 2007
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2007
    • Site details revised at 3 of 3 sites
    v3
  3. Start date: Jun 2007 to not statedv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers. Volunteers will be vaccinated by DNA-C and NYVAC-C vaccines, and the immune changes will be assessed, as well as safety of the vaccines. Volunteers will be followed during 72 weeks.
Trial Details
NCT Number NCT00490074
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: EuroVacc Foundation
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 147 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov